Spots Global Cancer Trial Database for stage i bladder cancer
Every month we try and update this database with for stage i bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer | NCT00003759 | Bladder Cancer | BCG vaccine valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00003725 | Bladder Cancer | valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Suramin in Treating Patients With Recurrent Bladder Cancer | NCT00006476 | Bladder Cancer | suramin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer | NCT00033436 | Bladder Cancer | niacinamide carbogen radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection | NCT00303654 | Bladder Cancer | biopsy therapeutic con... | - | National Cancer Institute (NCI) | |
| Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | NCT00088946 | Bladder Cancer | Polyphenon E erlotinib hydro... Erlotinib place... Polyphenon E | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | NCT02808143 | Recurrent Bladd... Stage 0a Bladde... Stage 0is Bladd... Stage I Bladder... | BCG Solution Laboratory Biom... Pembrolizumab Pharmacological... | 18 Years - | Northwestern University | |
| Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | NCT00088946 | Bladder Cancer | Polyphenon E erlotinib hydro... Erlotinib place... Polyphenon E | 18 Years - | Jonsson Comprehensive Cancer Center | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery | NCT01108003 | Recurrent Bladd... Stage 0 Bladder... Stage I Bladder... Stage II Bladde... Transitional Ce... | broccoli sprout... laboratory biom... Mango Juice | 18 Years - | Roswell Park Cancer Institute | |
| AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer | NCT00003759 | Bladder Cancer | BCG vaccine valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer | NCT01196403 | Bladder Cancer | questionnaire a... quality-of-life... robot-assisted ... therapeutic con... therapeutic lap... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | NCT00352079 | Bladder Cancer | BCG vaccine gefitinib quality-of-life... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer | NCT00981656 | Bladder Cancer | cisplatin 5-fluorouracil Mitomycin Three-Dimension... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | NCT00003129 | Bladder Cancer | valrubicin | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder | NCT00084578 | Bladder Cancer | celecoxib rosiglitazone m... conventional su... neoadjuvant the... | 18 Years - | Fox Chase Cancer Center | |
| Gene Therapy in Treating Patients With Advanced Bladder Cancer | NCT00003167 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... Transitional Ce... | Ad5CMV-p53 gene | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer | NCT00002490 | Bladder Cancer | BCG vaccine mitomycin C radiation thera... | - | National Cancer Institute (NCI) | |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | NCT00072137 | Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom... | - | National Cancer Institute (NCI) | |
| Paclitaxel in Treating Patients With Early-Stage Bladder Cancer | NCT00002917 | Bladder Cancer | paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer | NCT00095589 | Bladder Cancer | loss of heteroz... microarray anal... microsatellite ... cytology specim... laboratory biom... computed tomogr... cystoscopy | 40 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection | NCT00303654 | Bladder Cancer | biopsy therapeutic con... | - | National Cancer Institute (NCI) | |
| Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer | NCT00553345 | Bladder Cancer | selenium vitamin E chemoprevention | 18 Years - | National Cancer Institute (NCI) | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00003725 | Bladder Cancer | valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | NCT00072137 | Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... | Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom... | - | National Cancer Institute (NCI) | |
| Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer | NCT00004154 | Bladder Cancer | Fenretinide Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer | NCT00666562 | Stage I Bladder... Stage II Bladde... Stage III Bladd... | Defined Green T... Laboratory Biom... Pharmacological... Placebo Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | NCT00003129 | Bladder Cancer | valrubicin | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | NCT00042887 | Bladder Cancer | mitomycin C conventional su... | - 80 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer | NCT00729287 | Bladder Cancer | selenium placebo | 18 Years - 100 Years | KU Leuven | |
| Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer | NCT00553566 | Bladder Cancer | medical chart r... questionnaire a... study of socioe... | 18 Years - | National Cancer Institute (NCI) | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00003725 | Bladder Cancer | valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | NCT00352079 | Bladder Cancer | BCG vaccine gefitinib quality-of-life... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer | NCT00033436 | Bladder Cancer | niacinamide carbogen radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Bladder Cancer | NCT00003779 | Bladder Cancer | Connaught Tice | 18 Years - 90 Years | Swiss Group for Clinical Cancer Research | |
| Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer | NCT00095589 | Bladder Cancer | loss of heteroz... microarray anal... microsatellite ... cytology specim... laboratory biom... computed tomogr... cystoscopy | 40 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer | NCT01094964 | Bladder Cancer | BCG solution recombinant int... epirubicin hydr... mitomycin C laboratory biom... hyperthermia tr... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Gene Therapy in Treating Patients With Advanced Bladder Cancer | NCT00003167 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... Transitional Ce... | Ad5CMV-p53 gene | 18 Years - | National Cancer Institute (NCI) | |
| Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery | NCT01108003 | Recurrent Bladd... Stage 0 Bladder... Stage I Bladder... Stage II Bladde... Transitional Ce... | broccoli sprout... laboratory biom... Mango Juice | 18 Years - | Roswell Park Cancer Institute | |
| 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00005047 | Bladder Cancer | cisplatin doxorubicin hyd... methotrexate vinblastine | - 120 Years | SWOG Cancer Research Network | |
| AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer | NCT00003759 | Bladder Cancer | BCG vaccine valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| Quality of Life in Patients With Bladder Cancer | NCT00553215 | Bladder Cancer | quality-of-life... questionnaire a... | 18 Years - | National Cancer Institute (NCI) | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer | NCT00553124 | Bladder Cancer | selenium vitamin E biopsy chemoprevention cryopreservatio... cytology specim... diagnostic proc... gene expression... immunohistochem... laboratory biom... medical chart r... mutation analys... polymerase chai... quality-of-life... questionnaire a... study of socioe... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | NCT00042887 | Bladder Cancer | mitomycin C conventional su... | - 80 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | NCT02808143 | Recurrent Bladd... Stage 0a Bladde... Stage 0is Bladd... Stage I Bladder... | BCG Solution Laboratory Biom... Pembrolizumab Pharmacological... | 18 Years - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
